Second and third medical termination of pregnancy with misoprostol without mifepristone.
BACKGROUND
Advances in prenatal diagnosis make it possible to detect many fetal pathologies for which a termination of pregnancy (TOP) is possible in France. In pregnancies which go beyond 3 months, the use of prostaglandins combined with mifepristone has simplified this procedure. Since mifepristone must be taken 48 h before using prostaglandins, we have used only misoprostol intravaginally.


METHODS
Our report deals with a continuous series of terminated pregnancies in the second and third trimesters. The time period in question is January 1, 1996 through July 31, 2001. When this treatment was used within the first 30 weeks of gestation, four tablets (800 microg) of misoprostol were administered intravaginally. When there were no contractions, two additional tablets (400 microg) of misoprostol were given orally every 3 h, not exceeding 3 times. Beyond 30 weeks of amenorrhoea, because of the risk of uterine rupture, the initial dose was lower: 1/4 tablet (50 microg) of misoprostol intravaginally was increased to 100 microg (1/2 tablet) every 3 h until expulsion.


RESULTS
In the second and third trimesters, 55 pregnancies were terminated medically; only 1 case was not successful. In the other 54 cases, the average time interval between administering misoprostol intravaginally and expulsion was 12.7 +/- 8 h. Side effects included nausea or vomiting for 12 patients (22%) and hyperthermia for 11 patients (20%). Thirty-three patients (60%) had no side effects at all. In 10 cases (18%), the fetus and the placenta were removed in one movement. In 11 cases (20%), the placenta had to be removed by artificial means. In 7 cases (13%), a curettage with a curette foam was done. In the long run perspective, only 1 patient needed a curettage to remove placental residue.


CONCLUSIONS
Treatment by misoprostol without mifepristone during the second and third trimesters makes it possible to terminate a pregnancy easily and quickly without significant complications.
Langer
Bruno R
BR
Département de Gynécologie-Obstétrique, Hôpital de Hautepierre 1, avenue Molière, FR-67098 Strasbourg Cedex, France. Bruno.Langer@chru-strasbourg.fr
Peter
Christine
C
Firtion
Céline
C
David
Eric
E
Haberstich
Renaud
R
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects; D000028:Abortion, Induced; D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015735:Mifepristone; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D012189:Retrospective Studies; D013997:Time Factors
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol; D015735:Mifepristone